Chima Oleru, MD
Nephrology · Jackson, TNNPI 1841268299
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,496 of the $1,681 with a category attached, or 89.0%. It is spread thinly across 12 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $458 and has fallen 52.8% since, to $216 in 2025.
Across 27 payments — averaging $62.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$245
- AstraZeneca$233
- Nxstage Medical, Inc.$177
- Travere Therapeutics, Inc.$168
- Nuwellis, Inc.$153
- Calliditas Therapeutics US Inc.$135
- plus $571 from 6 others
What the payments were for
- Food & beverage$1,49689%
- Education$18511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 2 | $245 |
| AstraZeneca | 3 | $233 |
| Nxstage Medical, Inc. | 2 | $177 |
| Travere Therapeutics, Inc. | 9 | $168 |
| Nuwellis, Inc. | 1 | $153 |
| Calliditas Therapeutics US Inc. | 2 | $135 |
| OPKO Pharmaceuticals, LLC | 3 | $130 |
| Ardelyx, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $103 |
| Baxter Healthcare | 1 | $103 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $86 |
| Akebia Therapeutics Inc | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Aranesp$245
- AQUADEX SMARTFLOW CONSOLE$153
- XPHOZAH 30 MG$125
- LIBERTY SELECT CYCLER$125
- NXSTAGE SYSTEM ONE$125
- TARPEYO$123
- LOKELMA$112
- JYNARQUE$103
- Renal - Non Product Related$103
- FARXIGA$102
How this compares
$1,681 in reported general payments places this provider in the 55th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 88 | $60,300 |
| XphozahTenapanor Hcl | 12 | $34,850 |
| VeltassaPatiromer Calcium Sorbitex | 23 | $20,339 |
| Sevelamer Carbonate | 87 | $13,177 |
| Calcium Acetate | 156 | $8,622 |
| Calcitriol | 799 | $8,402 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $5,298 |
| Hydralazine Hcl | 158 | $2,447 |
| Losartan Potassium | 229 | $2,396 |
| Cinacalcet Hcl | 13 | $1,782 |
| Potassium Citrate ErPotassium Citrate | 17 | $1,538 |
| Potassium Chloride | 125 | $1,438 |
| Amlodipine Besylate | 295 | $1,333 |
| Labetalol Hcl | 57 | $1,272 |
| Midodrine Hcl | 38 | $1,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $233 | $65,598101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 229 nephrology providers in Tennessee.
Other nephrology in Jackson
- Victor NwazueJackson$7K
- Jamie DwyerNashville$461K
- Ross NesbitKnoxville$452K
- Gerald BorrelliKnoxville$190K
- Volker HaaseNashville$123K
- Chike NzerueCookeville$95K
- Talat IkizlerNashville$93K
- Omar HamzeMemphis$90K
- Julia LewisNashville$87K
- Osama El ShamyNashville$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.